SCHEMBL4288975

SCHEMBL4288975

CCCc1cc(C(=O)NCc2cccs2)no1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 1.00
NPC1 O15118 9/20 1.00
SMN1; SMN2 Q16637 6/20 1.00
POLB P06746 2/20 0.67
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
LMNA P02545 1/20 0.62
KDM4E B2RXH2 3/20 0.60
HPGD P15428 3/20 0.57
HSD17B10 Q99714 3/20 0.57
ALDH1A1 P00352 2/20 0.57
MAPT P10636 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
GAA P10253 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4291534 0.84 RAB9A (0.72) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL4288327 0.84 RAB9A (1.00) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL4286756 0.82 RAB9A (0.71) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL4278433 0.80 RAB9A (0.72) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL4283494 0.78 RAB9A (1.00) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL4281972 0.77 RAB9A (1.00) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL4280074 0.77 RAB9A (1.00) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL4286464 0.76 RAB9A (0.70) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL4284414 0.75 RAB9A (1.00) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL31162121 0.75 SMN1; SMN2 (0.69) RAB9ANPC1SMN1; SMN2POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same SIERRA SCIENCES, LLC (US) 2025-09-02 US disclosed
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same SIERRA SCIENCES, LLC 2025-06-05 US disclosed
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME SIERRA SCIENCES INC. 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same TERT, RNGTT, TERF2 RAB9A 4044/4885NPC1 2894/4885SMN1; SMN2 487/4885
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same TERT, TELO2, POT1 RAB9A 4662/4885NPC1 4442/4885SMN1; SMN2 1264/4885
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME TERT, TERF2, RNMT RAB9A 3970/4885NPC1 2996/4885SMN1; SMN2 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.